CLINICAL TRIALS PROFILE FOR NURTEC ODT
✉ Email this page to a colleague
All Clinical Trials for nurtec odt
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04629950 ↗ | Rimegepant in Moderate Plaque-type Psoriasis | Recruiting | Biohaven Pharmaceuticals, Inc. | Phase 2 | 2021-01-19 | The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication. |
NCT04629950 ↗ | Rimegepant in Moderate Plaque-type Psoriasis | Recruiting | Weill Medical College of Cornell University | Phase 2 | 2021-01-19 | The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication. |
NCT04860713 ↗ | An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute | Recruiting | Antonios Likourezos | Phase 4 | 2021-04-22 | Headaches affect over 50% of patients annually, with close to 4% of ED visits for headache. Most headaches managed in the ED are benign, with 90% of these headaches classified as tension, migraine, or cluster. At present, the satisfaction with ED treatment of headache is low, and despite the multitude of available medications, the evidence- based treatment options are often quite limited. There are over twenty different types of medications available to the ED clinicians for managing headache, many with different routes of administration (parenteral, intranasal, subcutaneous, and oral). Many of these medications are provided in so-called "headache cocktail", which varies based on the physician, institution, and patient preferences. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for nurtec odt
Condition Name
Clinical Trial Locations for nurtec odt
Trials by Country
Clinical Trial Progress for nurtec odt
Clinical Trial Phase
Clinical Trial Sponsors for nurtec odt
Sponsor Name